JUL 29, 2020 5:00 PM EDT

Enabling 3D T-Cell, Tumoroid Invasion, and Organoid Assays Through the Incorporation of Live Cellular Imaging

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Field Applications Scientist, BioTek Instruments
    Biography

      Brad has been at BioTek Instruments, INC. since 2009, first as a Principal Scientist in the Applications Group and most recently as a Field Scientist in the South Region. Brad’s early roles included optimizing new assay processes on BioTek’s line of automation, liquid handling, microplate detection, and imaging instrumentation, in addition to supporting new product development. Currently his role is supporting academic, biotech, and pharmaceutical researchers across five states. Prior to joining BioTek, he acquired extensive experience serving as an Automated Solutions Scientist and Applications Scientist with multiple reagent providers. During his 25 year career in the Biotech Industry he has worked with numerous automation and detection platforms, as well as a variety of cell models, to optimize 2D and 3D cell culture assays across multiple research fields. His current work has led to publications in Assay and Drug Development Technologies, The Journal of Laboratory Automation, The Journal of Biomolecular Screening, Cells, and Combinatorial Chemistry and High Throughput Screening, among others. Brad has additionally presented his work at numerous international conferences and workshops across the United States, Europe, and Asia.


    Abstract

    Over the last decade the cancer research field has seen a number of advances aimed at increasing the efficacy of treatments, reducing toxic side effects, and decreasing attrition rates of drug candidates. The first is the rise of immunotherapies which incorporate a patient’s own immune system to combat the cancer. In particular, adoptive immunotherapy techniques activate a patient’s T cells ex vivo against specific tumor antigens before infusing the activated T cells back into the patient to target and destroy tumor cells selectively. A second focus has been the incorporation of three dimensional (3D) in vitro testing models. Traditional use of 2D models many times led to attrition rates of drug candidates for cancer reaching 95%, stemming from in vitro drug efficacy values that did not translate to the clinic, as well as unforeseen toxicity issues. 3D models, by comparison, better mimic in vivo conditions found within the target patient, including oxygen and nutrient gradients, increased cell-to-cell and cell-to-ECM interactions, and non-uniform exposure of cells within a 3D structure to the test molecule. In this webinar, the attendee will learn how commonly performed in vitro cancer research procedures can be performed using advanced digital widefield microscopy.

    Three areas of focus will be covered:

    1. Monitoring directed T cell activation and cell mediated cytotoxicity using co-cultured T cells and 3D target cancer cell models

    2. 3D tumoroid invasion within a hydrogel

    3. Use of stem cell derived small intestinal organoids for toxicity assessment

    Proper label-free and fluorescence image capture techniques will be demonstrated, including the use of z-stacking and montaging to accurately visualize the 3D structures. Image and cellular analysis methods will also be shown to quantify metrics such as stem cell organoid budding, extent of tumoroid invasion, and T cell activation and induced target cell cytotoxicity.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 05, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 05, 2020 7:00 AM PST
    DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
    Loading Comments...
    Show Resources